Table of Contents

1 Report Overview

• 1.1 Study Scope
• 1.2 Key Market Segments
• 1.3 Players Covered
• 1.4 Market Analysis by Type
  • 1.4.1 Global Renal Diseases Drug Market Size Growth Rate by Type (2014-2025)
  • 1.4.2 Chronic Kidney Disease (CKD) Drugs
  • 1.4.3 End-Stage Kidney Disease (ESRD) Drugs
• 1.5 Market by Application
  • 1.5.1 Global Renal Diseases Drug Market Share by Application (2019-2025)
  • 1.5.2 Hospitals
  • 1.5.3 Specialty Clinics
  • 1.5.4 Other
• 1.6 Study Objectives
• 1.7 Years Considered

2 Global Growth Trends

• 2.1 Renal Diseases Drug Market Size
• 2.2 Renal Diseases Drug Growth Trends by Regions
  • 2.2.1 Renal Diseases Drug Market Size by Regions (2019-2025)
  • 2.2.2 Renal Diseases Drug Market Share by Regions (2014-2019)
• 2.3 Industry Trends
  • 2.3.1 Market Top Trends
  • 2.3.2 Market Drivers
  • 2.3.3 Market Challenges
  • 2.3.4 Porter’s Five Forces Analysis

3 Market Share by Key Players

• 3.1 Renal Diseases Drug Market Size by by Players
  • 3.1.1 Global Renal Diseases Drug Revenue by by Players (2014-2019)
  • 3.1.2 Global Renal Diseases Drug Revenue Market Share by by Players (2014-2019)
  • 3.1.3 Global Renal Diseases Drug Market Concentration Ratio (CR5 and HHI)
• 3.2 Renal Diseases Drug Key Players Head office and Area Served
• 3.3 Key Players Renal Diseases Drug Product/Solution/Service
• 3.4 Date of Enter into Renal Diseases Drug Market
• 3.5 Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Type and Application

• 4.1 Global Renal Diseases Drug Market Size by Type (2014-2019)
• 4.2 Global Renal Diseases Drug Market Size by Application (2014-2019)

5 North America

• 5.1 North America Renal Diseases Drug Market Size (2014-2019)
• 5.2 Renal Diseases Drug Key Players in North America
• 5.3 North America Renal Diseases Drug Market Size by Type
• 5.4 North America Renal Diseases Drug Market Size by Application

6 Europe

• 6.1 Europe Renal Diseases Drug Market Size (2014-2019)
• 6.2 Renal Diseases Drug Key Players in Europe
• 6.3 Europe Renal Diseases Drug Market Size by Type
• 6.4 Europe Renal Diseases Drug Market Size by Application

7 China

• 7.1 China Renal Diseases Drug Market Size (2014-2019)
• 7.2 Renal Diseases Drug Key Players in China
• 7.3 China Renal Diseases Drug Market Size by Type
• 7.4 China Renal Diseases Drug Market Size by Application

8 Japan

• 8.1 Japan Renal Diseases Drug Market Size (2014-2019)
• 8.2 Renal Diseases Drug Key Players in Japan
• 8.3 Japan Renal Diseases Drug Market Size by Type
• 8.4 Japan Renal Diseases Drug Market Size by Application

9 International Players Profiles

• 9.1 Pfizer
  • 9.1.1 Pfizer Company Details
  • 9.1.2 Company Description and Business Overview
  • 9.1.3 Renal Diseases Drug Introduction
  • 9.1.4 Pfizer Revenue in Renal Diseases Drug Business (2014-2019))
  • 9.1.5 Pfizer Recent Development
• 9.2 Amgen
  • 9.2.1 Amgen Company Details
  • 9.2.2 Company Description and Business Overview
  • 9.2.3 Renal Diseases Drug Introduction
  • 9.2.4 Amgen Revenue in Renal Diseases Drug Business (2014-2019)
  • 9.2.5 Amgen Recent Development
• 9.3 Roche
  • 9.3.1 Roche Company Details
  • 9.3.2 Company Description and Business Overview
  • 9.3.3 Renal Diseases Drug Introduction
  • 9.3.4 Roche Revenue in Renal Diseases Drug Business (2014-2019)
  • 9.3.5 Roche Recent Development
• 9.4 GlaxoSmithKline (GSK)
  • 9.4.1 GlaxoSmithKline (GSK) Company Details
  • 9.4.2 Company Description and Business Overview
  • 9.4.3 Renal Diseases Drug Introduction
  • 9.4.4 GlaxoSmithKline (GSK) Revenue in Renal Diseases Drug Business (2014-2019)
  • 9.4.5 GlaxoSmithKline (GSK) Recent Development
• 9.5 Allergan
  • 9.5.1 Allergan Company Details
  • 9.5.2 Company Description and Business Overview
  • 9.5.3 Renal Diseases Drug Introduction
  • 9.5.4 Allergan Revenue in Renal Diseases Drug Business (2014-2019)
  • 9.5.5 Allergan Recent Development
• 9.6 AbbVie
  • 9.6.1 AbbVie Company Details
  • 9.6.2 Company Description and Business Overview
  • 9.6.3 Renal Diseases Drug Introduction
  • 9.6.4 AbbVie Revenue in Renal Diseases Drug Business (2014-2019)
  • 9.6.5 AbbVie Recent Development
• 9.7 Kissei Pharmaceutical
  • 9.7.1 Kissei Pharmaceutical Company Details
  • 9.7.2 Company Description and Business Overview
  • 9.7.3 Renal Diseases Drug Introduction
  • 9.7.4 Kissei Pharmaceutical Revenue in Renal Diseases Drug Business (2014-2019)
  • 9.7.5 Kissei Pharmaceutical Recent Development
• 9.8 AstraZeneca
  • 9.8.1 AstraZeneca Company Details
  • 9.8.2 Company Description and Business Overview
  • 9.8.3 Renal Diseases Drug Introduction
  • 9.8.4 AstraZeneca Revenue in Renal Diseases Drug Business (2014-2019)
  • 9.8.5 AstraZeneca Recent Development
• 9.9 FibroGen
  • 9.9.1 FibroGen Company Details
  • 9.9.2 Company Description and Business Overview
  • 9.9.3 Renal Diseases Drug Introduction
  • 9.9.4 FibroGen Revenue in Renal Diseases Drug Business (2014-2019)
  • 9.9.5 FibroGen Recent Development
• 9.10 Sanofi
  • 9.10.1 Sanofi Company Details
  • 9.10.2 Company Description and Business Overview
  • 9.10.3 Renal Diseases Drug Introduction
  • 9.10.4 Sanofi Revenue in Renal Diseases Drug Business (2014-2019)
  • 9.10.5 Sanofi Recent Development
• 9.11 Teva Pharmaceutical Industries
• 9.12 Johnson & Johnson
• 9.13 Keryx Biopharmaceuticals

10 Market Forecast 2019-2025

• 10.1 Market Size Forecast by Product (2019-2025)
• 10.2 Market Size Forecast by Application (2019-2025)
• 10.3 Market Size Forecast by Regions
• 10.4 North America
• 10.5 Europe
• 10.6 China
• 10.7 Japan

11 Analyst's Viewpoints/Conclusions

12 Appendix

• 12.1 Research Methodology
  • 12.1.1 Methodology/Research Approach
    • 12.1.1.1 Research Programs/Design
    • 12.1.1.2 Market Size Estimation
    • 12.1.1.3 Market Breakdown and Data Triangulation
  • 12.1.2 Data Source
    • 12.1.2.1 Secondary Sources
    • 12.1.2.2 Primary Sources
• 12.2 Disclaimer

This report focuses on the global Renal Diseases Drug status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Renal Diseases Drug development in North America, Europe, China and Japan.

The key players covered in this study
Pfizer
Amgen
Roche
GlaxoSmithKline (GSK)
Allergan
AbbVie
Kissei Pharmaceutical
AstraZeneca
FibroGen
Sanofi
Teva Pharmaceutical Industries
Johnson & Johnson
Keryx Biopharmaceuticals

Market segment by Type, the product can be split into
Chronic Kidney Disease (CKD) Drugs
End-Stage Kidney Disease (ESRD) Drugs

Market segment by Application, split into
Hospitals
Specialty Clinics
Other

Market segment by Regions/Countries, this report covers
North America
Europe
China
Japan

The study objectives of this report are:
To analyze global Renal Diseases Drug status, future forecast, growth opportunity, key market and key players.
To present the Renal Diseases Drug development in North America, Europe, China and Japan.
To strategically profile the key players and comprehensively analyze their development plan and strategies.
To define, describe and forecast the market by product type, market and key regions.

In this study, the years considered to estimate the market size of Renal Diseases Drug are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.